![Dhavalkumar Patel](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Dhavalkumar Patel
Technik-/Wissenschafts-/F&E-Leiter bei
SANA BIOTECHNOLOGY, INC.
Vermögen: 328 383 $ am 31.05.2026
Profil
Dhavalkumar Patel gründete Priothera Ltd. Derzeit ist Dr. Patel Chief Scientific Officer & Executive VP bei UCB SA. Er ist außerdem im Vorstand von 6 weiteren Unternehmen. In seiner bisherigen Laufbahn war Dr. Patel Forschungsleiter bei Novartis Institutes for Biomedical Research, Inc. und Global Head-Autoimmunity bei Novartis International AG, Professor an der University of North Carolina at Chapel Hill und Professor am Duke University Medical Center. Dhavalkumar Patel erhielt einen Doktortitel, einen Bachelor- und einen Master-Abschluss von der Duke University.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
SANA BIOTECHNOLOGY, INC. 0,04 % | 24.03.2026 | 99.510 ( 0,04 % ) | 328 383 $ | 31.05.2026 |
Aktive Positionen von Dhavalkumar Patel
| Unternehmen | Position | Beginn |
|---|---|---|
| RA PHARMACEUTICALS, INC. | Direktor/Vorstandsmitglied | 02.04.2020 |
| SANA BIOTECHNOLOGY, INC. | Technik-/Wissenschafts-/F&E-Leiter | 26.08.2024 |
Kanyos Bio, Inc.
 Kanyos Bio, Inc. Pharmaceuticals: MajorHealth Technology Develops therapies for type 1 diabetes | Direktor/Vorstandsmitglied | - |
Anokion SA
 Anokion SA BiotechnologyHealth Technology Operates as a biotechnology company which develops therapies for antigen-specific immune tolerance | Direktor/Vorstandsmitglied | - |
Quell Therapeutics Ltd.
 Quell Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Operates as a biotechnology company which develops and supplies immune cell therapies to target transplant rejection, autoimmune and inflammatory diseases | Direktor/Vorstandsmitglied | - |
Mimetas BV
 Mimetas BV BiotechnologyHealth Technology Develops organ-on-a-chip technology for testing of new medicines in high-throughput on miniaturized organ and disease models | Vorsitzender | 01.09.2022 |
Ehemalige bekannte Positionen von Dhavalkumar Patel
| Unternehmen | Position | Ende |
|---|---|---|
| UCB | Technik-/Wissenschafts-/F&E-Leiter | 01.07.2024 |
Inflazome Ltd.
 Inflazome Ltd. Pharmaceuticals: MajorHealth Technology Develops therapeutic medicines for inflammatory diseases | Direktor/Vorstandsmitglied | 01.09.2020 |
Novartis International AG
 Novartis International AG Pharmaceuticals: MajorHealth Technology Offers healthcare solutions | Corporate Officer/Principal | 01.01.2017 |
| ░░░ ░░░░░░░░░░ ░░ ░░░░░ ░░░░░░░░ ░░ ░░░░░░ ░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ |
| ░░░░ ░░░░░░░░░░ ░░░░░░░ ░░░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ |
Ausbildung von Dhavalkumar Patel
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
79
Beziehungen ersten Grades
15
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 15 |
|---|---|
Novartis International AG
Novartis International AG Pharmaceuticals: MajorHealth Technology Offers healthcare solutions | Health Technology |
Ra Pharmaceuticals, Inc.
 Ra Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops drugs for the treatment of glomerulonephritis, kidney disease and cardiovascular disease | Health Technology |
Duke University
 Duke University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
UCB SA
 UCB SA Pharmaceuticals: MajorHealth Technology Manufactures biopharmaceutical products | Health Technology |
The University of North Carolina at Chapel Hill
 The University of North Carolina at Chapel Hill Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Novartis Institutes for Biomedical Research, Inc.
 Novartis Institutes for Biomedical Research, Inc. Miscellaneous Commercial ServicesCommercial Services Conducts biomedical researches | Commercial Services |
Duke University Medical Center
 Duke University Medical Center Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Duke University School of Medicine
 Duke University School of Medicine Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Anokion SA
Anokion SA BiotechnologyHealth Technology Operates as a biotechnology company which develops therapies for antigen-specific immune tolerance | Health Technology |
Mimetas BV
Mimetas BV BiotechnologyHealth Technology Develops organ-on-a-chip technology for testing of new medicines in high-throughput on miniaturized organ and disease models | Health Technology |
Kanyos Bio, Inc.
Kanyos Bio, Inc. Pharmaceuticals: MajorHealth Technology Develops therapies for type 1 diabetes | Health Technology |
Inflazome Ltd.
Inflazome Ltd. Pharmaceuticals: MajorHealth Technology Develops therapeutic medicines for inflammatory diseases | Health Technology |
Sana Biotechnology, Inc.
 Sana Biotechnology, Inc. BiotechnologyHealth Technology Operates as a biotechnological company which creates and delivers engineered cells as medicine for patients | Health Technology |
Quell Therapeutics Ltd.
Quell Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Operates as a biotechnology company which develops and supplies immune cell therapies to target transplant rejection, autoimmune and inflammatory diseases | Health Technology |
Priothera Ltd.
 Priothera Ltd. Pharmaceuticals: MajorHealth Technology Develops hematological malignancies cells | Health Technology |
Wählen Sie MarketScreener 
